Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cethromycin: Phase III data

In the double-blind, international Phase III CL-05 trial in patients with mild-to-moderate CAP, cethromycin

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE